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INTRODUCTION

INSOMNIA IS A PREVALENT HEALTH COMPLAINT, AND THE INCIDENCE INCREASES WITH AGING.
Normal age-related changes in sleep patterns, combined with the increased prevalence of health problems and medication use, place older adults at greater risk for developing sleep disturbances. Survey data indicate that between 12% and 25 % of healthy seniors-compared to 9% to 12% in the general population-experience chronic sleep difficulties. 1 Despite the availability of effective behavioral treatments for insomnia, pharmacotherapy remains the most widely used treatment method. 2 Benzodiazepine-receptor agonists are the most frequently prescribed drugs for insomnia, and, despite the advent of new nonbenzodiazepine agents (zolpidem, zaleplon, zopiclone), traditional benzodiazepines (BZ) are still widely prescribed for sleep. Although BZ can be indicated and effective for the short-term management of insomnia, 3 most patients for whom a hypnotic is prescribed, particularly older adults, continue using it for prolonged periods. 4, 5 Unfortunately, the effects of the chronic use of BZ on sleep continuity, architecture, and quality remain poorly documented.
Previous findings reported by our group 6, 7 have shown that the sleep electroencephalogram (EEG) recordings of older adults with subjective complaints of insomnia (medicated or not) was fairly similar to those of self-defined good sleepers (GS). Although a higher number of microarousals were found in BZ users (INSBZ) compared to drug-free insomnia sufferers (INS), sleep architecture and continuity parameters were similar between the two groups of insomnia sufferers, as well as in an age-matched control group composed of self-defined GS. Conversely, subjective (sleep diary) measures revealed significant differences on most sleep-continuity parameters, with both groups of insomnia sufferers reporting more difficulties initiating and maintaining sleep and less total sleep time, relative to GS. Moreover, INSBZ reported worse sleep quality than did INS. Such discrepancies between subjective and objective sleep measures, which have been reported by other researchers, 8, 9 may be due to the lack of precision in traditional sleep analyses, which may not be sensitive enough to detect subtle EEG changes contributing to the subjective sleep disturbances.
Power spectral analysis (PSA) may be a sensitive and powerful tool to evaluate the influence of such factors as age, medication use, and insomnia complaints on the EEG during sleep and to further circumscribe discrepancies between subjective and objective measures of sleep. For example, a higher rate of high-frequency activity (beta) and less slow-wave activity (delta and theta) have been found in young adults with insomnia relative to GS. [10] [11] [12] [13] Although not exclusive, the increased rate of high-frequency activity in the EEG of insomnia sufferers would be consistent with hyperarousal, a classic feature of this sleep disorder. 11, 14, 15 Acute and short-term BZ usage is associated with subjective improvements of quality and depth of sleep and freshness upon arising, 8 as well as with improved polysomnography (PSG)-defined sleep continuity and total sleep time. 8, 16 In addition, analyses of the sleep microstructure of short-term BZ users usually indicate an increase of beta and sigma activity and a decrease of delta activity. [17] [18] [19] To our knowledge, no study has yet documented the EEG power spectra in INSBZ. Furthermore, the effects of chronic use of BZ remain poorly documented, especially in older adults, a segment of the population particularly at risk for prolonged BZ usage. The aim of the present study is to further document the sleep microstructure of older adults with insomnia and using BZ on a chronic basis, in comparison with unmedicated insomniacs and GS.
METHOD Participants
The participants were divided in 3 groups: 15 individuals with insomnia and using BZ chronically (INSBZ; 7 men, 8 women), 15 drug-free individuals with insomnia (INS; 8 men, 7 women), and 16 self-defined good sleepers (GS; 9 men, 7 women). All participants were 55 years of age or older. Participants with insomnia had to meet the following inclusion criteria: a) subjective complaint of insomnia, defined as difficulties initiating or maintaining sleep or both; b) insomnia present at least 3 nights per week for more than 6 months; c) complaint of at least 1 negative daytime consequence attributed to insomnia, and d) distress or significant difficulties in occupational and social functioning. The INSBZ participants had to use BZ for at least 3 nights per week for more than 3 months. The INS participants had to be free from any hypnotic medications for at least 3 months before entering the study. The GS had no subjective sleep complaints, did not meet any criteria for insomnia, and did not use sleep-promoting agents. Exclusion criteria for all participants were a) a significant medical disorder, b) a major psychopathology, c) other sleep disorders, or d) use of another medication known to alter sleep. These criteria are consistent with those of the International Classification of Sleep Disorders 20 and the Diagnostic and Statistical Manual of Mental Disorders 21 for chronic primary insomnia and hypnoticdependent insomnia.
Procedure
All participants were recruited through media advertisements and physicians' referrals. The INSBZ participants were offered cognitive behavior therapy for insomnia with or without a tapering of their hypnotic medication. 22 The INS and GS were recruited as comparison groups for the present study and Vignola et al's study on the daytime consequences of insomnia. 23 Following a telephone screening, eligible participants completed a multistep clinical evaluation, including a psychological assessment, a sleep evaluation, and a medical history. The Structured Clinical Interview for DSM-IV 24 was administered to rule out major psychopathology. Participants completed daily sleep diaries for a minimum 2-week baseline period and the Insomnia Severity Index (ISI). 25 Those meeting study criteria underwent 3 consecutive nights of PSG recording in the sleep laboratory.
Measures
The ISI 25 is composed of 7 items that evaluate: (a) the severity of initial, (b) middle, (c) and late insomnia; (d) satisfaction with current sleep pattern; (e) interference with daily functioning; (f) noticeability of impairment attributed to the sleep problem; and (g) level of distress caused by the sleep problem. Each of these items is rated on a 5-point Likert scale ("0" = Not at all, "4" = Extremely). Total scores range from 0 to 28, with high scores indicating greater insomnia severity. The ISI has adequate internal consistency (r = 0.77) and concurrent validity when compared to sleep-diary data (r = 0.42) and PSG measures (r = 0.45). 26 PSG recording. Participants completed 3 consecutive nights of PSG in the laboratory. The INSBZ were instructed to take their medication, as usual, on PSG recording nights. A standard PSG montage including electroencephalographic (EEG) (C3-O1, C4-O2), electrooculographic (both infraorbital and supraorbital ridges), and electromyographic (submental) monitoring was used. The signal was amplified with Grass 78 and Neurodata Model 12 amplifiers. Low-and high-pass filters were set at 0.3 and 100, respectively, for EEG recordings. The PSG recordings were digitalized at a sampling rate of 200 Hz. Sleep stages were scored by two experienced sleep technicians, blinded to participants' condition, according to standardized criteria of Rechtschaffen and Kales, 27 using a 30-second epoch length. Respiration and anterior tibialis electromyographs were recorded during the first night of recording, which was used as an adaptation and screening night to detect sleep apnea and periodic limb movements. Participants with a respiratory index or periodic limb index exceeding 15 (in association with microarousals) were excluded from the study.
PSA procedures and methods. Since the first night was used as the screening night, PSAs were conducted on the second-night recordings only. The PSAs were carried out on 46 sleep EEG recordings. The nonrapid eye movement (REM) sleep (stages 2, 3, and 4) of the first 4 cycles were retained for spectral analysis. The PSA was carried out using Stellate Systems software TM , Harmonie-Sensa (version 3.1). Fast Fourrier transformations (FFT) were carried out on the C3-A2 lead. Power spectra were computed for consecutive 2.56-second epochs with no overlap. A cosine tapering was used. The record length was set at 28.16 seconds with a restart interval of 30 seconds The spectra, expressed in absolute power, were then divided into six frequency bands: delta (0 -3.9 Hz), theta (3.9-7.02), alpha (7.02-11.7), sigma (11.7-14.04), beta 1 (14.04-21.84), and beta 2 (21.84-30.03). Artifacts, including extreme REMs and muscular or cardiac activity, were visually removed from the EEG. Other EEG segments that may have contained artifacts were removed using HarmAct TM , software specially developed for this type of artifact removal. However, a technical trade-off was imposed. By using HarmAct to remove all possible artifacts (and EEG frequency of the higher 35-100 Hz range) to get the 'cleanest' EEG segments, only absolute power data were available from PSA.
Unless specified otherwise, the significance level was set at α = .05 for all comparisons.
RESULTS
Descriptive Variables
Participants were community-dwelling older adults with a mean age of 62.9 years (SD = 5.8) and an average education of 12.8 years (SD = 3.9); they were predominantly married (76.7%) and retired (70.0%). The types of insomnia reported by sufferers were mainly mixed difficulties (maintenance and early morning insomnia, 77%), sleep-maintenance insomnia (10%), sleep-onset insomnia (7%), and early morning insomnia (7%). Mean insomnia duration for the poor sleepers groups was 24.6 years (SD = 19.4). Participants in the INSBZ group had used BZ for sleep an average of 6.6 nights a week (SD = 1.1) for a mean duration of 13.5 years (SD = 10.0; range, 1-34). The BZ used were lorazepam, flurazepam, nitrazepam, and temazepam; the average nightly dosage was 1.6 mg (SD = 1.2) (lorazepam equivalent). Without exception, participants in the INSBZ group all used BZ for sleep on each of the nights of PSG recordings. Table 1 summarizes descriptive statistics on selected demographic and sleep variables. One-way analyses of variance (ANOVAs) and a chisquare analysis revealed that the three groups were equivalent as far as age, education, and gender. However, groups were significantly different on responses to the Beck Anxiety Inventory (F (2,42) = 8.07, p = .001) and the Beck Depression Inventory (F (2,42) = 22.00, p = .000). Posthoc analysis revealed that both groups of insomnia sufferers presented more anxiety and depressive symptoms than did the GS. Although not significant, t tests for independent samples showed that insomnia duration tended to be longer (t (20) = 2,028, sig = .06) for INS (M = 27.8 years, SD = 17.7) than for INSBZ (M = 17.5 years, SD = 8.3). The age of onset of insomnia was also similar in both groups of insomnia sufferers (INS, = 36.3 years, SD = 17.7 and INSBZ = 44.9 years, SD = 11.3). There were significant group differences on the ISI, F (2, 38) = 1.85 (p< .01). Posthoc comparisons using Sheffé's tests showed that the two insomnia groups, as expected, reported more severe sleep difficulties than did the GS (p < .01). However, sleep difficulties were equivalent in users and nonusers of BZ. Table 2 . There are significant differences among the groups on the percentage of time spent in stage 2 and stages 3 and 4 sleep (F (2, 43) = 4.27 and 4.83, respectively). Posthoc comparisons using Sheffé's tests showed that the INSBZ spend more time in Stage 2 and less time in Stage 3 and 4 sleep than did the GS. Moreover, there was a significant group difference in the hourly rate of microarousals F (2, 41) = 5.5 (p< .01). A higher count of microarousals was observed in INSBZ compared to INS and GS. The three groups were equivalent on all other dependent measures of sleep architecture. Furthermore, considering that BZ intake can affect respiratory effort, oneway ANOVAs were run on the hourly count of respiratory index (apneas and hypopneas) and respiratory index associated with microarousals. All groups were equivalent on respiratory index 
PSA
One-way ANOVAs were performed on the average absolute power for each frequency band during the 4 cycles and for the total night mean on the combined non-REM sleep stages, 2, and 3 and 4 ( Figure 1 ). Significant group differences were found for delta power within cycles 2 and 3, Fs (2, 43) = 10.5 and 6.5, respectively (p< .01) and for theta power within cycles 1, 2 and 3, Fs (2, 43) = 3.5, 6.9, and 4.6, respectively (p< .05). Posthoc comparisons using Sheffé's tests revealed that INSBZ had significantly less delta power in cycles 2 and 3 (p< .01) and less theta power in cycles 1, 2, and 3 (p< .05) than did GS. When compared to INS, the INSBZ presented less delta and theta activity within cycle 2 (p< .05). For sigma activity, there was a trend toward a significant group difference in cycle 4, F (2, 36) = 3,2 (p = .06), with the INSBZ showing more sigma power than did the GS (p = .08). Regarding high-frequency bands, results showed significant group differences for beta 1 activity within cycle 3, F (2, 43) = 3.8, (p< .05) and cycle 4, F (2, 36) = 5.3 (p< .05). Posthoc comparisons showed that INSBZ had significantly more beta 1 activity within cycle 3 than did GS and more than the INS and GS in cycle 4 (ps< .05). Consistent with the above results, significant group differences were also found for mean delta and theta powers for the total night, F (2,43) = 6.3 and 4.7, respectively (p< .01). Posthoc comparisons revealed that INSBZ had significantly less delta and theta activities over the entire night than did GS (p< .05). There were no significant group differences for sigma and beta 1 total night mean powers because higher rates in the INSBZ were mainly concentrated at the end of the night (cycles 3 and 4). However, beta 1 values in the INSBZ showed a tendency to be higher over the night than in the GS, F (2, 43) = 3.0, (p = .06). One-way ANOVAs were performed in order to explore in which sleep stages (2 vs. 3 and 4) absolute frequency band power differed (Table 3) . Results showed significant group differences for delta activity in stage 2 and a trend toward a significant difference for delta activity in stages 3 and 4, F (2, 43) = 5.6 (p< .01) and F (2, 37) = 2.9 (p = .07), respectively. Posthoc comparisons revealed less delta activity in stage 2 for INSBZ compared to GS (p < .05) and a trend in the same direction when compared to INS (p= .07). Significant group differences were observed for theta power in stage 2, F (2, 43) = 4.6 (p< .05), with the INSBZ group displaying less theta activity compared to GS and INS (p < .05). For beta 1 activity, significant group differences were observed in cycles 3 and 4, and there was a trend in the same direction for the total night, but there was no difference in the mean absolute power within each stage throughout the night. There were no significant group differences for the alpha, sigma, and beta 2 absolute powers.
DISCUSSION
This study compared sleep microstructure among medicated and unmedicated older adults with insomnia, relative to GS. The main results obtained are that BZ users have significantly less delta and theta activity over the entire night than do GS. When compared to INS, INSBZ have less delta and theta activity within cycle 2 only. Regarding high-frequency bands, there is a trend for the beta 1 values over the night to be higher for INS relative to GS. Results show that INSBZ have significantly more beta 1 activity within cycle 3 than do GS and more than INS and GS in cycle 4.
Although the short-term benefit of BZ use on sleep continuity is well documented, these drugs do not normalize sleep. 8 For example, they increase stage 2, decrease stages 3 and 4, and interfere with the production of slow-wave sleep, especially after repeated administration. Finally, BZ drugs increase sigma activity, activity that is usually associated with sleep protection from external stimulation. Our results, based on PSA, partly corroborate these previous findings. For example, INSBZ have significantly less delta and theta power compared to INS and GS. Furthermore, beta 1 activity is higher in the later part of the night for INSBZ in comparison to GS (cycles 3 and 4) and INS (cycle 4). Finally, alpha, sigma, and beta 2 activity are equivalent across the three groups throughout the night, except for a tendency among INSBZ to present more sigma activity at the end of the night. Thus, as reported by others, [17] [18] [19] 28 sleep architecture remains disrupted even after prolonged use of BZ.
Previous studies have found only slight differences on standard PSG measures between individuals with and without insomnia complaints. 7 It is plausible that visual scoring of PSG records using standard Rechtschaffen and Kales 27 sleep-stage criteria may not be sensitive enough to detect differences between those two groups. Nonetheless, one study has shown that the sleep microstructure is faster in INSBZ compared to GS sleepers or INS. 18 Using PSA, the present study confirms those findings in showing an increased beta 1 activity, mainly observed within cycles 3 and 4, and a decrease in slow-wave activity.
The age of our sample (55 or older) could explain the absence of more difference between INS and GS. Indeed, it is possible that sleep changes associated with insomnia are not easily distinguishable from structural alterations associated with aging alone. Although no objective differences are observed on EEG measures, the subjective measures of insomnia (diaries and ISI) clearly discriminate those two groups. These discrepancies are reported in other studies as well. 9, 11 As suggested by a recent study, 29 it might be that the subjective perception of sleep difficulties is explained by subtle changes in the EEG. These authors found an age-related reduction in power delta, theta, and sigma density over non-REM periods. An increase in high-frequency power spectral density was also observed, without a notable reduction in subjective sleep quality. They proposed that elevated beta activity marks higher cortical activation during sleep with aging, which may precede the onset of subjective sleep complaints. This suggests that the subtle EEG changes might exceed a threshold in power limits of high-frequency bands and, thereafter, translate in the perception of unsatisfying sleep.
Merica et al 11 suggested that a deficiency in slow-wave activity and an increment of faster EEG frequencies characterize insomnia. In the present study, the duration of the different stages (minutes) within each cycle obtained from PSG evaluations and values obtained from PSA are similar for INS and GS. Although our results do not corroborate those of Merica et al, 11 this may be due to a difference in the age of the respective samples. Other investigators have also observed that fast activity increases at the sleep-onset period in insomniacs. 10, 14 Unfortunately, the sleep period analyzed in the present study was limited to stages 2, 3, and 4 within the first 4 cycles. PSA should also be conducted on the wake period before sleep onset, during sleep-stage 1, and during REM sleep. Such recordings would allow the determination of the extent to which sleep complaints are due to cortical arousal, to sleep-state misperception, or to both.
Merica et al 11 did observe significant decreases in delta and theta values in insomniacs compared to GS but, as in the present study, did not observe any differences in sigma power between groups in non-REM sleep. Their significant differences in sigma were observed in REM sleep. Merica and colleagues first explained their results according to the work of Steriade et al, 30 suggesting a progressive hyperpolarization of the thalamocortical cell membranes as sleep deepens, moving from sigma frequencies to delta frequencies. Secondly, Merica et al 11 suggested that the delta deficiency might respond to some homeostatic regulation and control. Regarding our results, these suggestions might imply that chronic BZ use is very disturbing to the EEG and, especially, by affecting the hyperpolarization process, this process being already modified with age. The 'no effects' on sigma frequencies, might further be blurred by age and some specific central nervous system plasticity changes associated with it. Furthermore, homeostatic tendency in slowwave activity might still be operative all night but be deficient in INSBZ compared to older GS and INS.
Additional studies with young adults (medicated and unmedicated insomnia sufferers, and GS) are needed to further clarify the effects of age and insomnia on the microstructure of sleep. Moreover, adding frequency bands in the PSA (eg, higher than 30 Hz) would allow us to more clearly delineate the effects of age and hyperarousal. Previous studies have observed differences on gamma frequencies (over 30 Hz) associated with insomnia, BZ use, and cortical arousal manifestation. 12, 13, 29 In summary, our findings have several theoretical and clinical implications. First, they illustrate that PSA is an efficient and sensitive tool to quantify the effects of BZ use on sleep structure, particularly among older adults, a group for whom macrostructure sleep alterations due to physiologic aging are hard to distinguish from sleep changes specifically induced by insomnia, the use of hypnotic drugs, or both. Moreover, the findings raise important questions about the effects and indications of pro- longed utilization of hypnotic medication in elderly people. The decrement of slow-wave activity, the increment of high-frequency band, and the subtle increment of sigma activity might reflect poorer sleep quality and explain why chronic BZ users still subjectively perceive their sleep as disturbed, even with the use of BZ. These findings confirm the hypothesis that BZ users show a higher cortical activity. Long-term use of hypnotics continues to alter EEG microstructure, and there is little evidence of physiologic habituation over time.
